A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
Engineering dendritic cells (DCs) to treat cancer is a long sought-after goal for cell-based immunotherapies. In this review, we focus on the experience with CMN-001, formally AGS-003, a DC-based immunotherapy, employing autologous DC electroporated with autologous tumor RNA to treat subjects with m...
Saved in:
Main Authors: | Mark DeBenedette (Author), Alicia Gamble (Author), Marcus Norris (Author), Joe Horvatinovich (Author), Charles A. Nicolette (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
by: C. Gay, et al.
Published: (2019) -
mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy
by: Kosuke Sasaki, et al.
Published: (2022) -
Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response
by: Jacoba G Slagter-Jäger, et al.
Published: (2013) -
Dendritic Cell-Derived Exosomes in Cancer Immunotherapy
by: Shumin Luo, et al.
Published: (2023) -
Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells
by: João Calmeiro, et al.
Published: (2020)